Published in Genes Brain Behav on June 03, 2009
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina. Naunyn Schmiedebergs Arch Pharmacol (2013) 1.58
Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology (2011) 1.57
Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol (2013) 1.16
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A (2014) 1.13
Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci U S A (2012) 1.12
Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.03
CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol (2011) 1.02
The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99
CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? Mol Pharmacol (2014) 0.93
Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders. Curr Neuropharmacol (2011) 0.92
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci (2011) 0.91
Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events. J Neuroimmune Pharmacol (2011) 0.90
Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS. Curr Neuropharmacol (2011) 0.90
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res (2013) 0.89
Dietary conditions and highly palatable food access alter rat cannabinoid receptor expression and binding density. Physiol Behav (2011) 0.88
hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation. Chem Biol (2010) 0.87
Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain. Front Mol Neurosci (2011) 0.84
CB₂: therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.83
Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience (2015) 0.82
Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol (2013) 0.82
Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats. Addict Biol (2016) 0.82
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct (2014) 0.81
Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities. Neuropathol Appl Neurobiol (2011) 0.81
Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management. Mayo Clin Proc (2015) 0.81
Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry (2014) 0.81
Endocannabinoids are Involved in Male Vertebrate Reproduction: Regulatory Mechanisms at Central and Gonadal Level. Front Endocrinol (Lausanne) (2014) 0.80
Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats. Neuropsychopharmacology (2014) 0.80
The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci (2016) 0.79
Endocannabinoids and endovanilloids: a possible balance in the regulation of the testicular GnRH signalling. Int J Endocrinol (2013) 0.78
CB2 receptor activation inhibits melanoma cell transmigration through the blood-brain barrier. Int J Mol Sci (2014) 0.78
Antisense-mediated isoform switching of steroid receptor coactivator-1 in the central nucleus of the amygdala of the mouse brain. BMC Neurosci (2013) 0.78
Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. Transl Psychiatry (2016) 0.78
Effect of social odor context on the emission of isolation-induced ultrasonic vocalizations in the BTBR T+tf/J mouse model for autism. Front Neurosci (2015) 0.77
Endocannabinoid Signaling in Autism. Neurotherapeutics (2015) 0.76
The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief. ISRN Anesthesiol (2011) 0.76
Alternative RNA splicing: contribution to pain and potential therapeutic strategy. Drug Discov Today (2016) 0.76
Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) (2010) 0.76
The cannabinoid CB2 agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in mice. J Pharmacol Exp Ther (2017) 0.75
Brain cannabinoid receptor 2: expression, function and modulation. Acta Pharmacol Sin (2017) 0.75
The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice. Neurotox Res (2017) 0.75
Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. Front Neurosci (2017) 0.75
Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology (2017) 0.75
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A (2002) 20.48
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ (2001) 4.81
Adverse effects of cannabis. Lancet (1998) 4.58
Evolutionary fate of retroposed gene copies in the human genome. Proc Natl Acad Sci U S A (2006) 4.03
Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell (2008) 3.63
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res (2006) 2.62
Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci (2006) 2.07
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. Hippocampus (2009) 1.98
Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol (1997) 1.71
Cannabinoid receptors: where they are and what they do. J Neuroendocrinol (2008) 1.63
Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am J Med Genet B Neuropsychiatr Genet (2005) 1.60
Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther (2000) 1.52
CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol (2003) 1.39
Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol (2007) 1.34
Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol (1999) 1.30
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol (2007) 1.25
Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta (1996) 1.23
Evolutionary origins of the endocannabinoid system. Gene (2006) 1.21
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett (1995) 1.20
Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J Neurosci Methods (2008) 1.19
Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse (2008) 1.13
Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta (2002) 1.12
The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett (1995) 1.10
Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol (2007) 1.07
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr Med Chem (2008) 1.05
Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res (1990) 1.00
Cannabis, cannabinoids and reproduction. Prostaglandins Leukot Essent Fatty Acids (2004) 0.97
Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience (2007) 0.95
Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse Sertoli cells. Endocrinology (2003) 0.94
Molecular biology of cannabinoid receptors. Handb Exp Pharmacol (2005) 0.93
Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol (2008) 0.92
Cannabinoid receptors and their endogenous ligands. J Biochem (2002) 0.91
Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life Sci (2004) 0.89
Identification of a long stretch of homopurine.homopyrimidine sequence in a cluster of retroposons in the human genome. J Mol Biol (1990) 0.86
Tempo and mode in the endocannaboinoid system. J Mol Evol (2007) 0.84
Effects of delta 9-tetrahydrocannabinol on copulatory behavior and neuroendocrine responses of male rats to female conspecifics. Pharmacol Biochem Behav (1994) 0.83
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet (2000) 5.26
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A (1997) 3.26
A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction. Gene (1991) 3.16
Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics (1992) 2.55
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res (2006) 2.41
VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A (1997) 2.34
Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A (1998) 2.22
Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A (2001) 2.19
Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci (1993) 2.16
An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy (2004) 2.10
Cloning of the gamma-aminobutyric acid (GABA) rho 1 cDNA: a GABA receptor subunit highly expressed in the retina. Proc Natl Acad Sci U S A (1991) 2.10
Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry (2008) 2.07
Opioid peptide enkephalin: immunohistochemical mapping in rat central nervous system. Proc Natl Acad Sci U S A (1977) 2.07
Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families. Neurology (2008) 2.00
Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet (2000) 1.92
Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem (1997) 1.86
Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci U S A (1992) 1.79
Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry (2004) 1.78
Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci U S A (1993) 1.75
cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett (1994) 1.72
The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci (1996) 1.70
Linkage and association of febrile seizures to the IMPA2 gene on human chromosome 18. Neurology (2004) 1.57
Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI((-/-)) mice. Arterioscler Thromb Vasc Biol (2001) 1.52
CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology (2003) 1.50
Association between a new polymorphism in the activation-induced cytidine deaminase gene and atopic asthma and the regulation of total serum IgE levels. J Allergy Clin Immunol (2001) 1.47
Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet (1999) 1.46
Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem (1997) 1.44
Significant evidence for linkage of mite-sensitive childhood asthma to chromosome 5q31-q33 near the interleukin 12 B locus by a genome-wide search in Japanese families. Genomics (2000) 1.41
mu opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci U S A (1993) 1.39
Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett (1994) 1.39
Genetic polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR) and risk of vitiligo in Han Chinese populations: a genotype-phenotype correlation study. Br J Dermatol (2014) 1.39
D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry (1996) 1.38
Cloning of an apparent splice variant of the rat N-methyl-D-aspartate receptor NMDAR1 with altered sensitivity to polyamines and activators of protein kinase C. Proc Natl Acad Sci U S A (1992) 1.37
gamma-Aminobutyric acid A or C receptor? gamma-Aminobutyric acid rho 1 receptor RNA induces bicuculline-, barbiturate-, and benzodiazepine-insensitive gamma-aminobutyric acid responses in Xenopus oocytes. Mol Pharmacol (1992) 1.35
-mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem (1994) 1.35
Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J Neurosci (2001) 1.34
Fetal nucleated cells in maternal peripheral blood: frequency and relationship to gestational age. Hum Genet (1993) 1.33
Cholecystokinin octapeptide-like immunoreactivity: histochemical localization in rat brain. Proc Natl Acad Sci U S A (1979) 1.32
Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.31
Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry (2000) 1.30
Regional and subcellular distributions of brain neurotensin. Life Sci (1976) 1.28
The mu-opioid receptor is necessary for [D-Pen2,D-Pen5]enkephalin-induced analgesia. Eur J Pharmacol (1997) 1.26
A clinical, genetic, and neuropathologic study in a family with 16q-linked ADCA type III. Neurology (2005) 1.26
Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience (2002) 1.26
Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl) (2001) 1.26
Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology (1985) 1.24
Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. Am J Respir Crit Care Med (1997) 1.24
Retained cocaine conditioned place preference in D1 receptor deficient mice. Neuroreport (1995) 1.23
Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J Biol Chem (1996) 1.23
Dopamine transporter immunoreactivity in rat brain. J Comp Neurol (1995) 1.23
Copy number variation at 22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders. Mol Psychiatry (2013) 1.22
Fetal nucleated cells in maternal peripheral blood after delivery. Am J Obstet Gynecol (1994) 1.22
Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology (2001) 1.20
Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet (1997) 1.19
A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res Mol Brain Res (1992) 1.18
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia (2006) 1.16
Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Arch Gen Psychiatry (1992) 1.16
ADAM33 polymorphisms are associated with asthma susceptibility in a Japanese population. Clin Exp Allergy (2006) 1.16
Biomarkers for smoking cessation. Clin Pharmacol Ther (2013) 1.15
Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey. Breast Cancer Res Treat (2011) 1.15
The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J Neurosci (1997) 1.15
An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia. Mol Psychiatry (2002) 1.14
Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J (2006) 1.14
High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet (1997) 1.14
The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav (1989) 1.13
Bradykinin-like immunoreactive neuronal systems localized histochemically in rat brain. Proc Natl Acad Sci U S A (1979) 1.13
Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/kappa chimeras. J Biol Chem (1994) 1.12
Neurotensin: immunohistochemical localization in rat central nervous system. Proc Natl Acad Sci U S A (1977) 1.11
Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann N Y Acad Sci (2008) 1.11
Knockout of the mu opioid receptor enhances the survival of adult-generated hippocampal granule cell neurons. Neuroscience (2006) 1.10
A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun (1999) 1.10
Suprachiasmatic nucleus vasopressin messenger RNA: circadian variation in normal and Brattleboro rats. Science (1986) 1.10
Pharmacology of GABA rho 1 and GABA alpha/beta receptors expressed in Xenopus oocytes and COS cells. Br J Pharmacol (1993) 1.09
Human high molecular weight kininogen as a thiol proteinase inhibitor: presence of the entire inhibition capacity in the native form of heavy chain. Biochemistry (1986) 1.09
Inflammation enhances peripheral mu-opioid receptor-mediated analgesia, but not mu-opioid receptor transcription in dorsal root ganglia. Eur J Pharmacol (1995) 1.08
Methylation analysis of the fragile X syndrome by PCR. Genet Test (1999) 1.08
Vasopressin mRNA in situ hybridization: localization and regulation studied with oligonucleotide cDNA probes in normal and Brattleboro rat hypothalamus. Proc Natl Acad Sci U S A (1985) 1.07
Electromobility of plasmid DNA in tumor tissues during electric field-mediated gene delivery. Gene Ther (2002) 1.07
Phenotypic diversity and kinetics of proliferating microglia and astrocytes following cortical stab wounds. Glia (1996) 1.06
Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci (2008) 1.06
Marijuana: medical implications. Am Fam Physician (1999) 1.06
Fatal bacteria granuloma after trauma: a new entity. Br J Dermatol (2002) 1.06
Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter. J Comp Neurol (1999) 1.06
Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet (1998) 1.05
Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav (2003) 1.05
Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy (1998) 1.04
Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area. J Neurosci (1997) 1.04
Ultrastructural immunocytochemical localization of mu-opioid receptors in rat nucleus accumbens: extrasynaptic plasmalemmal distribution and association with Leu5-enkephalin. J Neurosci (1996) 1.04
The proportion of fetal nucleated red blood cells in maternal blood: estimation by FACS analysis. Prenat Diagn (1997) 1.03
[Abnormal branching of left pulmonary artery to the lateral and posterior basal segments]. Nihon Kyobu Geka Gakkai Zasshi (1996) 1.03
Brain transcription factor expression: effects of acute and chronic amphetamine and injection stress. Brain Res Mol Brain Res (1993) 1.03